Equities analysts predict that TapImmune Inc. (NASDAQ:MRKR) will announce earnings of ($0.13) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for TapImmune’s earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.12). TapImmune reported earnings per share of ($0.41) in the same quarter last year, which suggests a positive year-over-year growth rate of 68.3%. The company is expected to report its next quarterly earnings report on Thursday, August 8th.
On average, analysts expect that TapImmune will report full-year earnings of ($0.51) per share for the current fiscal year, with EPS estimates ranging from ($0.58) to ($0.46). For the next year, analysts expect that the company will report earnings of ($0.51) per share, with EPS estimates ranging from ($0.75) to ($0.39). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover TapImmune.
TapImmune (NASDAQ:MRKR) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.05.
NASDAQ:MRKR traded down $0.04 during midday trading on Friday, reaching $4.26. 447,065 shares of the company traded hands, compared to its average volume of 935,856. TapImmune has a twelve month low of $4.18 and a twelve month high of $10.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 19.73 and a quick ratio of 19.73. The firm has a fifty day moving average of $7.12.
An institutional investor recently raised its position in TapImmune stock. Riggs Asset Managment Co. Inc. raised its holdings in shares of TapImmune Inc. (NASDAQ:MRKR) by 68.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,919 shares of the company’s stock after acquiring an additional 18,650 shares during the period. Riggs Asset Managment Co. Inc. owned approximately 0.10% of TapImmune worth $303,000 as of its most recent SEC filing. 33.59% of the stock is currently owned by institutional investors.
TapImmune Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Recommended Story: Conference Calls and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.